Form 4: Director Melinda Brown Reports Vesting and Settlement of Restricted Stock Units in Precision Biosciences Inc.

Melinda Brown, a director of Precision Biosciences Inc., reported the vesting and settlement of 4,202 Restricted Stock Units (RSUs) on May 4, 2024, resulting in the acquisition of 4,202 shares of common stock.

Summary

• On May 4, 2024, Melinda Brown, a director of Precision Biosciences Inc. (DTIL), had 4,202 Restricted Stock Units (RSUs) vest and settle.
• This resulted in the acquisition of 4,202 shares of Precision Biosciences Inc.'s common stock.
• The RSUs were granted on May 4, 2023, and vested in full on May 4, 2024.
• The reported amounts of securities have been adjusted to reflect a 1-for-30 reverse stock split that occurred on February 13, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock options vesting. It doesn't inherently convey positive or negative sentiment.

Positives

• The vesting of RSUs indicates that the director has met certain performance or time-based milestones set by the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The vesting of RSUs is a common form of equity compensation.

Stakeholder Impact

• The vesting of RSUs dilutes existing shareholders' equity, although the impact is likely minimal given the relatively small number of shares involved.

Key Dates